Escalation to weekly dosing recaptures response in adalimumab-treated patients with moderately to severely active ulcerative colitis

Alimentary Pharmacology and Therapeutics

Volumn 40, Issue 5, 2014, Pages 486-497

  Wolf, D ^a   D'Haens, G ^b,c   Sandborn, W J ^d   Colombel, J F ^e   Van Assche, G ^f,g   Robinson, A M ^h   Lazar, A ^h   Zhou, Q ^h   Petersson, J ^h   Thakkar, R B ^h  

^a Atlanta Gastroenterology Associates   (United States)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c Imelda GI Clinical Research Center   (Belgium)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF TORONTO   (Canada)

^g UNIVERSITY OF LEUVEN   (Belgium)

^h ABBVIE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; COLITIS, ULCERATIVE; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84905815846     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12863     Document Type: Article

References (23)

1. Lichtenstein GR, Rutgeerts P,. Importance of mucosal healing in ulcerative colitis. Inflamm Bowel Dis 2010; 16: 338-46.
2. Peyrin-Biroulet L, Ferrante M, Magro F, et al,. Results from the 2nd Scientific Workshop of the ECCO. I: impact of mucosal healing on the course of inflammatory bowel disease. J Crohns Colitis 2011; 5: 477-83.
3. Reinisch W, Sandborn WJ, Hommes DW, et al,. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 2011; 60: 780-7.
4. Sandborn WJ, van Assche G, Reinisch W, et al,. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012; 142: 257-65.
5. Feagan BG, Sandborn WJ, Lazar A, et al,. The effect of adalimumab therapy on the risk of hospitalization in patients with ulcerative colitis. Gastroenterology 2014; 146: 110-8.
6. Rutgeerts P, Sandborn WJ, Feagan BG, et al,. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462-76.
7. Reinisch W, Sandborn WJ, Panaccione R, et al,. 52-Week efficacy of adalimumab in patients with moderately to severely active ulcerative colitis who failed corticosteroids and/or immunosuppressants. Inflamm Bowel Dis 2013; 8: 1700-9.
8. Sandborn WJ, Feagan BG, Marano C, et al,. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2014; 146: 85-95.
9. Sandborn WJ, Feagan BG, Marano C, et al,. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2014; 146: 96-109.
10. Yanai H, Hanauer SB,. Assessing response and loss of response to biological therapies in IBD. Am J Gastroenterol 2011; 106: 685-98.
11. Sandborn WJ, Colombel JF, Schreiber S, et al,. Dosage adjustment during long-term adalimumab treatment for Crohn's disease: clinical efficacy and pharmacoeconomics. Inflamm Bowel Dis 2011; 17: 141-51.
12. Dubinsky M, Rosh JR, Faubion WA, et al,. Rate of and response to dose escalation in pediatric patients with Crohn's disease from IMAgINE 1. Gastroenterology 2014; 146: S-26.
13. Sandborn WJ, Colombel JF, D'Haens G, et al,. One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2. Aliment Pharmacol Ther 2013; 37: 204-13.
14. Ordas I, Mould DR, Feagan BG, Sandborn WJ,. Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms. Clin Pharmacol Ther 2012; 91: 635-46.
15. AbbVie. Humira (adalimumab): US prescribing information. Available at: http://www.rxabbvie.com/pdf/humira.pdf. Accessed May 2014.
16. Humira-Summary of Product Characteristics. Available at: http://www.medicines.org.uk/emc/medicine/21201/SPC/Humira+Pre-filled+Pen%2c+Pre- filled+Syringe+and+Vial/. Accessed May 2014.
17. Torres J, Billioud V, Sachar DB, Peyrin-Biroulet L, Colombel JF,. Ulcerative colitis as a progressive disease: the forgotten evidence. Inflamm Bowel Dis 2012; 18: 1356-63.
18. Nagalingam NA, Lynch SV,. Role of the microbiota in inflammatory bowel diseases. Inflamm Bowel Dis 2012; 18: 968-84.
19. Ordas I, Feagan BG, Sandborn WJ,. Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease. Clin Gastroenterol Hepatol 2012; 10: 1079-87.
20. Colombel JF, Feagan BG, Sandborn WJ, Van Assche G, Robinson AM,. Therapeutic drug monitoring of biologics for inflammatory bowel disease. Inflamm Bowel Dis 2012; 18: 349-58.
21. Mostafa NM, Eckert D, Pradham RS, et al,. Exposure-efficacy relationship (ER) for adalimumab during induction phase of treatment of adult patients with moderate to severe ulcerative colitis. Digestive Disease Week. Gastroenterology 2013: 144 (Suppl. 1): S-235-6.
22. Armuzzi A, Biancone L 0, Daperno M, et al,. Adalimumab in active ulcerative colitis: a "real-life" observational study. Dig Liver Dis 2013; 45: 738-43.
23. Garcia-Bosch O, Gisbert JP, Canas-Ventura A, et al,. Observational study on the efficacy of adalimumab for the treatment of ulcerative colitis and predictors of outcome. J Crohns Colitis 2013; 7: 717-22.